Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.

Other Patient-Reported Symptoms Dupilumab maintained response in Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Hospital Anxiety and Depression Scale (HADS): differences (week 36 minus SOLO-CONTINUE baseline) showed further improvement from SOLO that was nominally significant for dupilumab weekly or every 2 weeks vs placebo; for example, for POEM, dupilumab weekly or every 2 weeks showed significant improvement (least squares mean change from baseline) of 0.3 vs −7.0 for placebo ( P < .001); for DLQI, dupilumab weekly or every 2 weeks showed improvement of 0.2 vs −3.1 for placebo ( P < .001); and for HADS, dupilumab weekly or every 2 weeks showed improvement of 0.8 vs −0.8 for placebo ( P = .01).

also in 7,732 other papers